DEC 06, 2018 10:05 AM PST

Repurposing Cancer Drugs For HPV Treatment

WRITTEN BY: Nouran Amin

Credit: Northwestern University "New Cures disrupts 'valley of death' by de-risking drugs for pharmaceutical and biomedical partnerships"

Drug repurposing is transforming the health care world. The idea that old, previously-- FDA approved drugs could be altered and to be used again for the treatment of other diseases has been for quiet sometime fairly successful.

Related: 'Drug Re-purposing' Shows Promising Treatment for Mesothelioma

Now, recent pre-clinical research at the University of Alabama-Birmingham (UAB), concluded that cancer inhibiting drugs vorinostat, belinostat and panobinostat may be useful for repurposing in the treatment of infections caused by human papillomaviruses, or HPVs.

According to the World Heath Organization, HPV infections in 2012 have resulted in 266,000 deaths from cervical cancer worldwide. Although in developed countries routine screening by Pap smears or through HPV DNA testing reduced the incidence of death in comparison to less developed regions—still an estimated 12,200 women in the US are plagued with cervical cancer each year.

Effective vaccines against HPV exist -- including the recently approved Gardasil 9 that protects against nine confirmed genotypes of HPV. However, such vaccine is only there therapeutically effective if administered before an individual is sexually active. "Safe, effective and inexpensive therapeutic agents are urgently needed," says lead author and assistant professor of Biochemistry and Molecular Genetics at UAB, N. Sanjib Banerjee, Ph.D.

Learn more about how the HPV vaccine works:

The UAB study discovered that the productive program of HPV is highly dependent on the differentiation of the infected site of the epithelium into a squamous epithelium. Therefore, the researchers used an HPV-18 model raft cultures and found that the vorinostat cancer drug inhibited HPV-18 DNA amplification and virus production. Additionally, it was found to result in the programmed cell death called apoptosis in some cells that were fully differentiated.

The researchers went on to use the two remaining cancer inhibiting drugs--belinostat and panobinostat--on the infected differentiated raft cultures. Similar to vorinostat, the drugs were observed to have the same effects.

"On the basis of these detailed studies, we suggest that HDAC inhibitors [vorinostat, belinostat and panobinostat] are promising compounds for treating benign HPV infections, abrogating progeny production and hence interrupting infectious transmission,” says Banerjee. "But further investigation would be required to verify that these agents could also be useful in treating HPV associated dysplasias and cancers.”

Source: University of Alabama-Birmingham, Proceedings of the National Academy of Sciences

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
DEC 02, 2019
Drug Discovery & Development
DEC 02, 2019
New Ultrasound Treatment for Parkinson's Tremors
A non-invasive ultrasound procedure may provide lasting relief from tremors in people with Parkinson’s disease (PD) and essential tremor (ET), accord...
DEC 20, 2019
Genetics & Genomics
DEC 20, 2019
Can We Cure Down's Syndrome with Gene Therapy?
Down’s Syndrome (DS) is a genetic disorder brought on by the presence of all of part of a third copy of chromosome 21. Linked to delays in physical g...
DEC 27, 2019
DEC 27, 2019
Using a Cancer Drug to Fight Antibiotic-Resistant Pathogens
It takes a long time for a drug to be approved for use in humans; repurposing existing drugs is one way to get around that hurdle....
JAN 15, 2020
Drug Discovery & Development
JAN 15, 2020
FDA Approves Drugs Faster than Ever- But is That Good?
The Food and Drug Administration (FDA) is approving new drugs for patients on less and less evidence thanks to special programs that streamline their appro...
JAN 20, 2020
Cell & Molecular Biology
JAN 20, 2020
Using Modified Red Blood Cells As a Drug Delivery System
For a drug to be effective, it has to get to the right place to exert its impact....
FEB 10, 2020
FEB 10, 2020
New hope for KRAS-mutant pancreatic cancers
A study published recently in the journal Cancer Research showcases the findings from new research on pancreatic cancer. The study was led by Frank Mc...
Loading Comments...